Alumis has filed for an IPO to fund Phase III trials of ESK-001, a drug targeting plaque psoriasis and other conditions.
The trials are set to begin in late 2024, with results expected in 2026. The company aims to position ESK-001 as a competitor to Bristol Myers Squibb's Sotyktu and Takeda's TAK-279, focusing on its potential in treating autoimmune diseases.
The proceeds from the IPO are also aimed at raising funds to support the development of another drug, A-005, for neurological diseases.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.